200 related articles for article (PubMed ID: 17212587)
1. Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1.
Nafz J; De-Castro Arce J; Fleig V; Patzelt A; Mazurek S; Rösl F
Biochem J; 2007 May; 403(3):501-10. PubMed ID: 17212587
[TBL] [Abstract][Full Text] [Related]
2. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner.
Sun Y; Connors KE; Yang DQ
Mol Cell Biochem; 2007 Dec; 306(1-2):239-45. PubMed ID: 17786544
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase.
Rattan R; Giri S; Singh AK; Singh I
J Biol Chem; 2005 Nov; 280(47):39582-93. PubMed ID: 16176927
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line.
Imamura K; Ogura T; Kishimoto A; Kaminishi M; Esumi H
Biochem Biophys Res Commun; 2001 Sep; 287(2):562-7. PubMed ID: 11554766
[TBL] [Abstract][Full Text] [Related]
5. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR.
Sakamoto K; Göransson O; Hardie DG; Alessi DR
Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E310-7. PubMed ID: 15068958
[TBL] [Abstract][Full Text] [Related]
6. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside stimulates tyrosine hydroxylase activity and catecholamine secretion by activation of AMP-activated protein kinase in PC12 cells.
Fukuda T; Ishii K; Nanmoku T; Isobe K; Kawakami Y; Takekoshi K
J Neuroendocrinol; 2007 Aug; 19(8):621-31. PubMed ID: 17620104
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase.
Yu SY; Chan DW; Liu VW; Ngan HY
Tumour Biol; 2009; 30(2):80-5. PubMed ID: 19407487
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
9. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Begg AC; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1515-23. PubMed ID: 21944462
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling.
Su RY; Chao Y; Chen TY; Huang DY; Lin WW
Mol Cancer Ther; 2007 May; 6(5):1562-71. PubMed ID: 17513605
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4-carboxamide riboside is independent of AMP-activated protein kinase.
Kuo CL; Ho FM; Chang MY; Prakash E; Lin WW
J Cell Biochem; 2008 Feb; 103(3):931-40. PubMed ID: 17615555
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
Zhuge J
Cell Biol Toxicol; 2009 Jun; 25(3):253-63. PubMed ID: 18473182
[TBL] [Abstract][Full Text] [Related]
13. The AMP-activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-b-D-ribonucleoside, regulates lactate production in rat Sertoli cells.
Galardo MN; Riera MF; Pellizzari EH; Cigorraga SB; Meroni SB
J Mol Endocrinol; 2007 Oct; 39(4):279-88. PubMed ID: 17909267
[TBL] [Abstract][Full Text] [Related]
14. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men.
Cuthbertson DJ; Babraj JA; Mustard KJ; Towler MC; Green KA; Wackerhage H; Leese GP; Baar K; Thomason-Hughes M; Sutherland C; Hardie DG; Rennie MJ
Diabetes; 2007 Aug; 56(8):2078-84. PubMed ID: 17513706
[TBL] [Abstract][Full Text] [Related]
15. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases.
Zajkowicz A; Rusin M
Mech Ageing Dev; 2011; 132(11-12):543-51. PubMed ID: 21945951
[TBL] [Abstract][Full Text] [Related]
16. Phenformin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) activation of AMP-activated protein kinase inhibits transepithelial Na+ transport across H441 lung cells.
Woollhead AM; Scott JW; Hardie DG; Baines DL
J Physiol; 2005 Aug; 566(Pt 3):781-92. PubMed ID: 15919715
[TBL] [Abstract][Full Text] [Related]
17. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression.
Igata M; Motoshima H; Tsuruzoe K; Kojima K; Matsumura T; Kondo T; Taguchi T; Nakamaru K; Yano M; Kukidome D; Matsumoto K; Toyonaga T; Asano T; Nishikawa T; Araki E
Circ Res; 2005 Oct; 97(8):837-44. PubMed ID: 16151020
[TBL] [Abstract][Full Text] [Related]
18. α2 isoform-specific activation of 5'adenosine monophosphate-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside at a physiological level activates glucose transport and increases glucose transporter 4 in mouse skeletal muscle.
Nakano M; Hamada T; Hayashi T; Yonemitsu S; Miyamoto L; Toyoda T; Tanaka S; Masuzaki H; Ebihara K; Ogawa Y; Hosoda K; Inoue G; Yoshimasa Y; Otaka A; Fushiki T; Nakao K
Metabolism; 2006 Mar; 55(3):300-8. PubMed ID: 16483872
[TBL] [Abstract][Full Text] [Related]
19. A pharmacological activator of AMP-activated protein kinase (AMPK) induces astrocyte stellation.
Favero CB; Mandell JW
Brain Res; 2007 Sep; 1168():1-10. PubMed ID: 17706943
[TBL] [Abstract][Full Text] [Related]
20. Intracerebroventricular infusion of glucose, insulin, and the adenosine monophosphate-activated kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, controls muscle glycogen synthesis.
Perrin C; Knauf C; Burcelin R
Endocrinology; 2004 Sep; 145(9):4025-33. PubMed ID: 15192044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
